Go to The Journal of Clinical Investigation
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
  • Physician-Scientist Development
  • Current issue
  • Past issues
  • By specialty
    • COVID-19
    • Cardiology
    • Immunology
    • Metabolism
    • Nephrology
    • Oncology
    • Pulmonology
    • All ...
  • Videos
  • Collections
    • In-Press Preview
    • Resource and Technical Advances
    • Clinical Research and Public Health
    • Research Letters
    • Editorials
    • Perspectives
    • Physician-Scientist Development
    • Reviews
    • Top read articles

  • Current issue
  • Past issues
  • Specialties
  • In-Press Preview
  • Resource and Technical Advances
  • Clinical Research and Public Health
  • Research Letters
  • Editorials
  • Perspectives
  • Physician-Scientist Development
  • Reviews
  • Top read articles
  • About
  • Editors
  • Consulting Editors
  • For authors
  • Publication ethics
  • Publication alerts by email
  • Transfers
  • Advertising
  • Job board
  • Contact
Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors
Katja Pekrun, … , Markus Grompe, Mark A. Kay
Katja Pekrun, … , Markus Grompe, Mark A. Kay
Published November 14, 2019
Citation Information: JCI Insight. 2019;4(22):e131610. https://doi.org/10.1172/jci.insight.131610.
View: Text | PDF
Resource and Technical Advance Therapeutics

Using a barcoded AAV capsid library to select for clinically relevant gene therapy vectors

  • Text
  • PDF
Abstract

While gene transfer using recombinant adeno-associated viral (rAAV) vectors has shown success in some clinical trials, there remain many tissues that are not well transduced. Because of the recent success in reprogramming islet-derived cells into functional β cells in animal models, we constructed 2 highly complex barcoded replication competent capsid shuffled libraries and selected for high-transducing variants on primary human islets. We describe the generation of a chimeric AAV capsid (AAV-KP1) that facilitates transduction of primary human islet cells and human embryonic stem cell–derived β cells with up to 10-fold higher efficiency compared with previously studied best-in-class AAV vectors. Remarkably, this chimeric capsid also enabled transduction of both mouse and human hepatocytes at very high levels in a humanized chimeric mouse model, thus providing a versatile vector that has the potential to be used in both preclinical testing and human clinical trials for liver-based diseases and diabetes.

Authors

Katja Pekrun, Gustavo De Alencastro, Qing-Jun Luo, Jun Liu, Youngjin Kim, Sean Nygaard, Feorillo Galivo, Feijie Zhang, Ren Song, Matthew R. Tiffany, Jianpeng Xu, Matthias Hebrok, Markus Grompe, Mark A. Kay

×

Figure 7

In vivo transduction efficiency of rAAVs packaged with the AAV8 and AAV-DJ capsids.

Options: View larger image (or click on image) Download as PowerPoint
In vivo transduction efficiency of rAAVs packaged with the AAV8 and AAV-...
Balb/C SCID mice were injected via tail vein with 2 × 1010 vg each FLuc-expressing rAAV, and luciferase expression in the livers was monitored over several weeks using live imaging after i.p injection of luciferin substrate. Four animals were injected for each group, with the exception of the AAV8 group, which contained 3 animals. The mean of each group’s mean ventral radiance is shown for each time point, with SDs indicated. One animal from the AAV8 group was omitted from analysis due to a failed substrate injection. Experimental values were assessed via 2-way ANOVA using Tukey’s multiple comparisons test. Only statistically significant differences are indicated in the legend below the graph. **P < 0.01.

Copyright © 2025 American Society for Clinical Investigation
ISSN 2379-3708

Sign up for email alerts